{
    "nct_id": "NCT03141671",
    "official_title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)",
    "inclusion_criteria": "* Histologically confirmed prostate cancer\n* PSA ≥ 0.1 after radical prostatectomy (value w/in 3 months of registration) AND at least 1 unfavorable risk factor listed below.\n\n  * Gleason 8-10\n  * PSA > 0.5\n  * Pathologically positive lymph nodes\n  * pT3 or pT4\n  * PSA doubling time (DT) < 10 months\n  * Negative margins\n  * Persistent PSA after RP (PSA never dropped below 0.1 after RP)\n  * Local/regional recurrence on imaging\n  * Decipher \"High risk\" (a Medicare-reimbursed test for risk of metastases after prostatectomy)\n* Candidate for salvage radiation and ADT treatment\n* Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Subject must have the ability to understand and willingness to sign the written informed consent document.\n* 18 ≤ Age ≤ 95 at the time of consent\n* ECOG Performance Status ≤ 2 (Appendix A)\n* Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 3 months of registration.\n* System Laboratory Value\n* Hematological:\n\n  * Platelet count (plt) ≥ 100,000/ µL\n  * Hemoglobin (Hgb) ≥ 9 g/dL\n  * Absolute neutrophil count (ANC) ≥ 1000 cells/µL\n* Renal:\n\n  --GFR1 ≥ 45 mL/min\n* Hepatic and Other:\n\n  * Bilirubin2 ≤ 1.5 × upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) ≤ 2.5 × ULN\n  * Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n  * Serum Albumin > 3.0 g/dL\n  * Serum potassium ≥ 3.5 mmol/L\n* Coagulation:\n\n  * International Normalized Ratio (INR)\n  * or Prothrombin Time (PT)\n* Activated Partial Thromboplastin Time\n\n  * (aPTT) ≤ 1.5 × ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)\n  * Cockcroft-Gault formula will be used to calculate creatinine clearance (see study procedure manual SPM)\n  * In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤1.5 × ULN, subject may be eligible\n* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug.\n* Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.\n* Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee\n* Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry (Section 5.5)\n* Use of CYP3A4 inhibitors or inducers and CYP2D6 substrates must be discontinued prior to study entry\n* Able to swallow pills\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 95 Years",
    "exclusion_criteria": "* Use of post-prostatectomy ADT for > 30 continuous days prior to registration (ADT defined as use of GnRH agonist, with or without an anti-androgen). However, patients with testosterone recovery after post-prostatectomy ADT are eligible (testosterone recovery defined as total testosterone > 190 ng/dL) regardless of how long they have been on ADT.\n* Prior pelvic radiation unless additional radiation can be safely delivered according to the treating physician\n* PSA > 15 ng/mL in screening\n* History of any of the following:\n\n  * Seizure or known condition that may predispose to seizure (e.g., prior stroke within 1 year of randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)\n  * Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization\n* Current evidence of any of the following:\n\n  * Uncontrolled hypertension\n  * Gastrointestinal disorder affecting absorption\n  * Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis)\n  * Any chronic medical condition requiring a dose of corticosteroid higher than 10 mg prednisone/prednisolone once daily\n  * Any condition that, in the opinion of the site investigator, would preclude participation in this study\n  * Moderate or severe hepatic impairment (Child Pugh Class B or C)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness or social situations that would limit compliance with study requirements\n* Individuals with a history of another malignancy are not eligible if:\n\n  * the cancer is under active treatment or\n  * the cancer can be seen on radiology scans or\n  * if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within 5 years\n* Confirmed bone metastases on imaging",
    "miscellaneous_criteria": ""
}